NCT04283773 · ADVERSE EVENTS

Adverse events

Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors. · Source last updated 2021-09-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 1 year
Other-event reporting threshold: 0%

Nature of specimen is paraffin embedded tissue blocks , therefore there is no mortality , harm or serious Adverse Events were obtained to the participants. This explained why "0" is a total number of Participants at Risk.

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Immunohistochemical Expression of P16 Expression in Malignant Ovarian Germ Cell Tumors. 22cases of malignant ovarian germ cell tumors ; 5 cases of dysgerminoma ( one of them is bilateral) , 9cases of yolk sac tumor and 8 cases of immature teratoma. These cases are treated by anti P16 antibody( p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267) , 1:500 concentration, over night duration and then treated by DAP secondary antibody . Finally assessed by visualized peroxidase method.	0 / 0	0 / 0	0 / 0
Immunohistochemical Expression of P16 Expression in Benign Ovarian Germ Cell (MCTs) 20 cases of mature cystic teratomas ; were treated by anti P16 antibody( p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267) , 1:500 concentration, over night duration and then treated by DAP secondary antibody . Finally assessed by visualized peroxidase method.	0 / 0	0 / 0	0 / 0
Immunohistochemical Expression of P16 Expression in Normal Ovarian Tissues. 20 cases of normal ovarian tissues were treated by anti P16 antibody( p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267) , 1:500 concentration, over night duration and then treated by DAP secondary antibody . Finally assessed by visualized peroxidase method.	0 / 0	0 / 0	0 / 0

Group identifiers: EG000: Immunohistochemical Expression of P16 Expression in Malignant Ovarian Germ Cell Tumors. · EG001: Immunohistochemical Expression of P16 Expression in Benign Ovarian Germ Cell (MCTs) · EG002: Immunohistochemical Expression of P16 Expression in Normal Ovarian Tissues.

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

event Groups

deaths Num Affected
0
deaths Num At Risk
0
description
22cases of malignant ovarian germ cell tumors ; 5 cases of dysgerminoma ( one of them is bilateral) , 9cases of yolk sac tumor and 8 cases of immature teratoma. These cases are treated by anti P16 antibody( p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267) , 1:500 concentration, over night duration and then treated by DAP secondary antibody . Finally assessed by visualized peroxidase method.
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Immunohistochemical Expression of P16 Expression in Malignant Ovarian Germ Cell Tumors.
deaths Num Affected
0
deaths Num At Risk
0
description
20 cases of mature cystic teratomas ; were treated by anti P16 antibody( p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267) , 1:500 concentration, over night duration and then treated by DAP secondary antibody . Finally assessed by visualized peroxidase method.
id
EG001
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Immunohistochemical Expression of P16 Expression in Benign Ovarian Germ Cell (MCTs)
deaths Num Affected
0
deaths Num At Risk
0
description
20 cases of normal ovarian tissues were treated by anti P16 antibody( p16INK4a Recombinant Rabbit Monoclonal Antibody (RM267) , 1:500 concentration, over night duration and then treated by DAP secondary antibody . Finally assessed by visualized peroxidase method.
id
EG002
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Immunohistochemical Expression of P16 Expression in Normal Ovarian Tissues.

frequency Threshold

time Frame

1 year

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice